期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型登革热疫苗临床前研发 被引量：1

Preclinical development of novel dengue vaccines
原文传递
导出
摘要 登革热已经成为全球重要的公共卫生问题，由于目前尚无有效的治疗方法，因此，研发登革热疫苗已成为控制该病研究的热点。如今，几个候选登革热疫苗正处于临床试验阶段。一些临床前候选疫苗可能成为高质量的新一代疫苗。此文介绍了登革热疫苗研发的各种技术，着重阐述了临床前疫苗的研发现状。 Dengue has become a major public health problem over the world, and there are no specific dengue therapeutics available so far. At present, several candidate vaccines have entered clinical trials. The second generation dengue vaccines may arise from the present preclinical candidates. In this review, technological approaches to dengue vaccine are described, specifically focusing on the preclinical vaccines.
作者 吴浩飞(综述) 孟胜利(审校)
机构地区 武汉生物制品研究所有限责任公司质量保证部 武汉生物制品研究所有限责任公司狂犬病疫苗室
出处 《国际生物制品学杂志》 CAS 2013年第3期123-127,共5页 International Journal of Biologicals
关键词 登革热病毒 EDⅢ蛋白 登革热疫苗 Dengue virus Domain Ⅲ protein Dengue vaccines
分类号 R512.8 [医药卫生—内科学]
  • 相关文献

参考文献21

  • 1Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine [ J]. Annu Rev Immunol, 2011, 29:587-619.
  • 2Whitehom J, Farrar J. Dengue [ J]. Br Med Bull, 2010, 95 : 161- 173.
  • 3Halstead SB. Antibodies determine virulence in dengue [J]. Ann N Y Acad Sci, 2009, 1171 Suppl 1 :E48-56.
  • 4Dowd KA, Pierson TC. Antibody-mediated neutralization of flaviviruses: a reductionist view [ J]. Virology, 2011, 411 (2): 306 -315.
  • 5Kuwahara M, Konishi E. Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens [ J]. Clin Vaccine Immunol, 2010, 17 (10) : 1560-1566.
  • 6Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines [J]. Expert Rev Vaccines, 2007, 6(2) : 255-266.
  • 7Brandler S, Ruffle C, Najburg V, et al. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses [ J]. Vaccine, 2010, 28 (41) : 6730-6739.
  • 8孟胜利(综述),孙燕(综述).登革病毒E蛋白结构域Ⅲ疫苗研究进展[J].国际生物制品学杂志,2011,34(2):72-76. 被引量：1
  • 9Bernardo L, Izquierdo A, Alvarez M, et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain Ⅲ of the dengue 1 envelope protein in non-human primates [J]. Antiviral Res, 2008, 80(2) :194-199.
  • 10Valdes I, Bernardo L, Gil L, et al. A novel fusion protein domain Ⅲ-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice [J].Virology, 2009, 394(2) :249-258.

二级参考文献31

  • 1Brandler S,Ruffle C,Najburg V,et al.Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses[J].Vaccine,2010,28(41):6730-6739.
  • 2Block OK,Rodrigo WW,Quinn M,et al.A tetravalent recombinant dengue domain Ⅲ protein vaccine stimulates neutralizing and enhancing antibodies in mice[J].Vaccine,2010,28(51):8085-8094.
  • 3Guzman MG,Hermida L,Beruardo L,et al.Domain Ⅲ of the envelope protein as a dengue vaccine target[J].Expert Rev Vaccines,2010,9 (2):137-147.
  • 4Ooi EE,Goh KT,Chee WD.Effect of increasing age on the trend of dengue and dengue hemorrhagic fever in Singapore[J].Int J Infect Dis,2003,7 (3):231-232.
  • 5Guzman MG,Halstead SB,Artsob H,et al.Dengue:a continuing global threat[J].Nat Rev Microbiol,2010,8(12Suppl):S7-16.
  • 6Whitehead SS,Blaney JE,Durbin AP,et al.Prospects for a dengue virus vaccine[J].Nat Rev Microbiol,2007,5(7):518-528.
  • 7Gonzalez D,Castro OE,Kouri G,et al.Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20years or more apart:Havana,Dengue 3 epidemic,2001-2002[J].Int J Infect Dis,2005,9(5):280-285.
  • 8Hombach J,Cardosa M J,Sabchareon A,et al.Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005[J].Vaccine,2007,25(21):4130-4139.
  • 9Guzman MG,Mune M,Kouri G.Dengue vaccine:priorities and progress[J].Expert Rev Anti Infect Ther,2004,2 (6):895-911.
  • 10Sabchareon A,Lang J,Chanthavanich P,et al.Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers:role of serotype concentration,ratio,and multiple doses[J].Am J Trop Med Hyg,2002,66(3):264-272.

同被引文献10

引证文献1

国际生物制品学杂志
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部